Department of Dermatology
Medical Center – University of Freiburg
Hauptstrasse 7
79104 Freiburg i. Brsg.
- +49 (0) 761/ 270 – 67850
- dimitra.kiritsi@uniklinik-freiburg.de
- Homepage
Current position
Consultant dermatologist & Group leader, Department of Dermatology, Medical Center – University of Freiburg
Academic training
| 2001 – 2007 | Study of Medicine in Athens, Greece |
Scientific qualifications
| 2016 | Habilitation in Dermatology, University of Freiburg |
| 2008 – 2011 | M.D., PhD in Experimental Dermatology, University of Freiburg |
Postgraduate Positions
| since 04/2023 | Professor of Dermatology, Aristotle University of Thessaloniki, Greece |
| since 2018 | Head of the Outpatient Clinic of the Department of Dermatology, Medical Center University of Freiburg |
| since 2016 | Head of the Wound Care Unit and the Laser Unit of the Department of Dermatology, Medical Center University of Freiburg |
| since 2015 | Consultant and head of the Immunofluorescence laboratory and the "Clinical Trial Center-Fragile Skin", Department of Dermatology, Medical Center - University of Freiburg |
| since 2014 | Fellow of the European Boarrd of Dermatology and Venerology |
| since 2013 | Group Leader, Department of Dermatology, Medical Center - University of Freiburg |
| 2011 – 2012 | Postdoctorate, Department of Dermatology, Medical Center - University of Freiburg |
| 2008 – 2014 | Dermatology Resident, Department of Dermatology, Medical Center - University of Freiburg |
Miscellaneous (Honors, Awards)
| 2020 | Participant of the “Berta-Ottenstein Programme for Advanced Clinician Scientists” of the University of Freiburg |
| 2017 | "Ingrid zu Solms-Prize for Medicine 2017" of the Ingrid zu Solms-Foundation |
| 2016 | “Habilitation Prize 2016“ of the Medical Center University of Freiburg |
| 2012 | Publication Prize of the Fondation La Roche-Posay 2012 for the publication: "Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination" by Kiritsi D et al, published in J Clin Invest, 122(5):1742-6. |
link to all publications from D. Kiritsi: Pubmed
Publications based on CRC1160 funding
Kiritsi D, Schauer F, Gewert S, Reineker K, Reimer-Taschenbrecker A, Schwieger-Briel A, Ott H, Schmoor C, Grishina O, Murrell D, Stiller B, Zahn T, Nyström A, Bruckner-Tuderman L. 2024. Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial. EClinicalMedicine. 2024 Oct 30;77:102900. doi: 10.1016/j.eclinm.2024.102900.
Zrelski MM, Hösele S, Kustermann M, Fichtinger P, Kah D, Athanasiou I, Esser PR, Wagner A, Herzog R, Kratochwill K, Goldmann WH, Kiritsi D, Winter L. 2024. Plectin Deficiency in Fibroblasts Deranges Intermediate Filament and Organelle Morphology, Migration, and Adhesion. J Invest Dermatol. 2024 Mar;144(3):547-562.e9. doi: 10.1016/j.jid.2023.08.020.
Zrelski MM, Hösele S, Kustermann M, Fichtinger P, Kah D, Athanasiou I, Esser PR, Wagner A, Herzog R, Kratochwill K, Goldmann WH, Kiritsi D, Winter L. 2023. Plectin Deficiency in Fibroblasts Deranges Intermediate Filament and Organelle Morphology, Migration, and Adhesion. J Invest Dermatol. S0022-202X(23)02585-X. doi: 10.1016/j.jid.2023.08.020.
Dieter K, Niebergall-Roth E, Daniele C, Fluhr S, Frank NY, Ganss C, Kiritsi D, McGrath JA, Tolar J, Frank MH, Kluth MA.2023. ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa. Cytotherapy. Mar 1:S1465-3249(23)00036-1. doi: 10.1016/j.jcyt.2023.01.015.
Schauer F, Tasiopoulou G, Schuster D, Behrens M, Müller S, Kiritsi D. 2023. Primate liver tissue substrate in indirect immunofluorescence diagnostics for patients with dermatitis herpetiformis and celiac disease. Front Immunol. Feb 16;14:1104360. doi: 10.3389/fimmu.2023.1104360.
Lehr, S., F. Meiss, D. Kiritsi, and L. Tsakiris. 2022. Small-Vessel Vasculitis After ST-Segment Elevation Myocardial Infarction: Clopidogrel or Amiodarone? JACC Case Rep 4: 967-971. doi: 10.1016/j.jaccas.2022.05.008.
Lehr, S., F. Felber, I. Tantcheva-Poor, C. Kessler, R. Eming, A. Nystrom, M. Rizzi, and D. Kiritsi. 2022. Occurrence of autoantibodies against skin proteins in patients with hereditary epidermolysis bullosa predisposes to development of autoimmune blistering disease. Front Immunol 13: 945176. doi: 10.3389/fimmu.2022.945176.
Susana Minguet, Alexander Nyström, Dimitra Kiritsi, Marta Rizzi. 2022. Inborn errors of immunity and immunodeficiencies: Antibody-mediated pathology and autoimmunity as a consequence of impaired immune reactions. Eur J Immunol, First published: 20 April 2022; doi.org/10.1002/eji.202149529
Schauer F, Nyström A, Kunz M, Hübner S, Scholl S, Athanasiou I, Alter S, Fischer J, Has C, Kiritsi D. 2022. Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita. Front Immunol. 13:883967. doi: 10.3389/fimmu.2022.883967.
Schauer, F., S. Mai, S. C. Hofmann, Y. Mai, K. Izumi, J. S. Kern, and D. Kiritsi. 2022. Autoreactivity to BP180 Neoepitopes in Patients With Pemphigoid Gestationis. JAMA Dermatol 158: 212-214. doi: 10.1001/jamadermatol.2021.5294.
Nyström A, Bruckner-Tuderman L, Kiritsi D. 2021. Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers. Front Genet. 12:737272. doi: 10.3389/fgene.2021.737272. eCollection 2021.
Kiritsi D, Tsakiris L, Schauer F. 2021. Plectin in Skin Fragility Disorders. Cells. 10(10):2738. doi: 10.3390/cells10102738.
Schauer F, Behrens M, Mueller S, Meiss F, Kiritsi D. 2021. Impact of the COVID-19 pandemic on hospitalizations of patients with moderate-to-severe skin diseases: A retrospective cohort analysis from a Central European Center. J Am Acad Dermatol. 86(1):245-248. doi: 10.1016/j.jaad.2021.09.032. Epub 2021 Sep 22.
Bernasconi R, Thriene K, Romero-Fernández E, Gretzmeier C, Kühl T, Maler M, Nauroy P, Kleiser S, Rühl-Muth A-C, Stumpe M, Kiritsi D, Martin SF, Hinz B, Bruckner-Tuderman L, Dengjel J, Nyström A. 2021. Pro-inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang-(1-7). EMBO Mol Med. e14392.
Egg D, Rump IC, Mitsuiki N, Rojas-Restrepo J, Maccari ME, Schwab C, Gabrysch A, Warnatz K, Goldacker S, Patiño V, Wolff D, Okada S, Hayakawa S, Shikama Y, Kanda K, Imai K, Sotomatsu M, Kuwashima M, Kamiya T, Morio T, Matsumoto K, Mori T, Yoshimoto Y, Dybedal I, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Lorenz HM, Sullivan KE, Heimall J, Moutschen M, Litzman J, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Snapper S, Giulino-Roth L, Svaton M, Platt CD, Hambleton S, Neth O, Gosse G, Reinsch S, Holzinger D, Kim YJ, Bakhtiar S, Atschekzei F, Schmidt R, Sogkas G, Chandrakasan S, Rae W, Derfalvi B, Marquart HV, Ozen A, Kiykim A, Karakoc-Aydiner E, Králíčková P, de Bree G, Kiritsi D, Seidel MG, Kobbe R, Dantzer J, Alsina L, Armangue T, Lougaris V, Agyeman P, Nyström S, Buchbinder D, Arkwright PD, Grimbacher B. 2021. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol. S0091-6749(21)00891-5.
Masmoudi, W., M. Vaillant, S. Vassileva, A. Patsatsi, G. Quereux, C. Moltrasio, C. Abasq, C. Prost-Squarcioni, D. Kottler, D. Kiritsi, N. Litrowski, P. Plantin, L. Friedrichsen, A. Zebrowska, S. Duvert-Lehembre, S. Hofmann, V. Ferranti, F. Jouen, P. Joly, V. Hebert, and E. A. B. S. D. T. Force. 2021. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid. Br J Dermatol 184: 1106-1112
Schauer, F., F. Meiss, K. Thoma, and D. Kiritsi. 2021. IL17 inhibition for psoriasis vulgaris and arthritis results in clinical and serological remission of coexistent pemphigus foliaceus. J Dermatol. doi: 10.1111/1346-8138.15801.
Nauroy, P., and D. Kiritsi. 2021. Research in practice: Towards deciphering the role of epidermal proteases in recessive dystrophic epidermolysis bullosa progression. J Dtsch Dermatol Ges. doi: 10.1111/ddg.14396.
Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, Tufa SF, Keene DR, Kiritsi D, Hainzl S, Murauer EM, Marinkovich MP, Platenburg G, Hausser I, Wally V, Ritsema T, Koller U, Haisma EM, Nyström A. 2020. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study. J Invest Dermatol. S0022-202X(20)32061-3. doi: 10.1016/j.jid.2020.08.018. Online ahead of print.
Nyström A, Kiritsi D. 2020. Transmembrane collagens – unexplored mediators of epidermal-dermal communication and tissue homeostasis. Exp Dermatol. doi: 10.1111/exd.14180. Online ahead of print.
